102 Alternatively, several groups are advocating for the incorporation of novel markers, for instance a elaborate karyotype55 or epigenetic subsets, 27,28 into medical practice. All of these novel prognostic and/or predictive versions will need to be validated in cohorts of clients addressed with focused agents.That notwithstanding, both of those s